Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis

References

• Carreras E, Fernandez-Aviles F, Silva L, et al. Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center. Bone Marrow Transplant. 2010;45:1417–1422.
   PubMed Web of Science ®Google Scholar
• Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:893–898.
   PubMed Web of Science ®Google Scholar
• Cornell RF, Hari P, Drobyski WR. Engraftment syndrome after autologous stem cell transplantation: an update unifying the definition and management approach. Biol Blood Marrow Transplant. 2015;21:2061–2068.
   PubMed Web of Science ®Google Scholar
• Lee CK, Gingrich RD, Hohl RJ, et al. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant. 1995;16:175–182.
   PubMed Web of Science ®Google Scholar
• Lopes da Silva R, Costa F, Ferreira G, et al. Post-autologous hematopoietic SCT engraftment syndrome: a single center experience. Bone Marrow Transplant. 2012;47:456–457.
   PubMed Web of Science ®Google Scholar
• Maiolino A, Biasoli I, Lima J, et al. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria. Bone Marrow Transplant. 2003;31:393–397.
   PubMed Web of Science ®Google Scholar
• Keyzner A, D'Souza A, Lacy M, et al. Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. Biol Blood Marrow Transplant. 2013;19:1395–1398.
   PubMed Web of Science ®Google Scholar
• Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124:374–384.
   PubMed Web of Science ®Google Scholar
• Irazabal MV, Eirin A, Gertz MA, et al. Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis. Am J Hematol. 2012;87:51–54.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Gastineau DA, et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant. 2000;26:963–969.
   PubMed Web of Science ®Google Scholar
• Cornell RF, Zhong X, Arce-Lara C, et al. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant. 2015;50:914–917.
   PubMed Web of Science ®Google Scholar
• Cornell RF, Hari P, Zhang MJ, et al. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2013;19:1368–1373.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Vicent M, Ramirez M, Sevilla J, et al. Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome. Bone Marrow Transplant. 2004;34:1051–1055.
   PubMed Web of Science ®Google Scholar
• Moreb JS, Kubilis PS, Mullins DL, et al. Increased frequency of autoaggression syndrome associated with autologous stem cell transplantation in breast cancer patients. Bone Marrow Transplant. 1997;19:101–106.
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58:1033–1045.
   PubMed Web of Science ®Google Scholar
• Ravoet C, Feremans W, Husson B, et al. Clinical evidence for an engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation. Bone Marrow Transplant. 1996;18:943–947.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989–995.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–4549.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26:2317–2325.
   PubMed Web of Science ®Google Scholar
• Rappeport J, Mihm M, Reinherz E, et al. Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors. Lancet. 1979;2:717–720.
   PubMed Web of Science ®Google Scholar
• Condomines M, Quittet P, Lu ZY, et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol. 2006;176:6631–6639.
   PubMed Web of Science ®Google Scholar
• Edenfield WJ, Moores LK, Goodwin G, et al. An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose. Bone Marrow Transplant. 2000;25:405–409.
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH, Trudel S, Reece DE, et al. Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation. Am J Hematol. 2011;86:873–875.
   PubMed Web of Science ®Google Scholar
• Keung YK, Beaty MW, Pettenati M, et al. Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature. Clin Lymphoma Myeloma Leuk. 2010;10:129–133.
   PubMed Web of Science ®Google Scholar
• Khan SA, Gaa B, Pollock BH, et al. Engraftment syndrome in breast cancer patients after stem cell transplantation is associated with poor long-term survival. Biol Blood Marrow Transplant. 2001;7:433–438.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Garcia G, Rovira M, Magnano L, et al. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018;53:1541–1547.
   PubMed Web of Science ®Google Scholar
• D'Souza A, Dispenzieri A, Wirk B, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study. J Clin Oncol. 2015;33:3741–3749.
   PubMed Web of Science ®Google Scholar